
RadNet RDNT
$ 57.63
2.11%
Annual report 2025
added 03-02-2026
RadNet Operating Income 2011-2026 | RDNT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income RadNet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 M | 105 M | 98.7 M | 46.4 M | 82.6 M | 35.7 M | 69.9 M | 30.9 M | 50 M | 38.5 M | 39.1 M | 10.7 M | 11.6 M | 12.6 M | 8.39 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 8.39 M | 46.8 M |
Quarterly Operating Income RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.4 M | 30.9 M | - | 33.9 M | 34.8 M | - | 43.3 M | 24.4 M | 6.67 M | - | 6.92 M | 19.6 M | -1.72 M | - | 32.6 M | 27.7 M | 17.7 M | - | 23.4 M | 179 K | -8.78 M | - | 16.8 M | 22 M | 7.27 M | - | 16.4 M | 15.9 M | -888 K | - | 10.8 M | 14.2 M | 6.75 M | - | 12.5 M | 8.08 M | 2.98 M | - | 17.2 M | 13.4 M | -1.95 M | - | 15.2 M | 15.6 M | 7.55 M | - | 8.59 M | 13 M | 8.32 M | - | 13.8 M | 13.5 M | 11.3 M | - | 11 M | 15.1 M | 8.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 43.3 M | -8.78 M | 14.5 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.65 | -1.84 % | $ 61.9 M | ||
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M | ||
|
Agilent Technologies
A
|
1.35 B | $ 115.55 | 1.0 % | $ 35.1 B | ||
|
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | ||
|
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
-50.2 M | $ 1.67 | -2.34 % | $ 2.22 M | ||
|
Castle Biosciences
CSTL
|
8.67 M | $ 24.46 | 3.25 % | $ 679 M | ||
|
CareDx, Inc
CDNA
|
-30.8 M | $ 21.23 | 5.83 % | $ 1.13 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
311 M | $ 84.33 | 1.82 % | $ 5.69 B | ||
|
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.31 | 1.75 % | $ 493 M | ||
|
Medpace Holdings
MEDP
|
535 M | $ 410.54 | 4.35 % | $ 11.8 B | ||
|
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
25.2 M | $ 169.8 | 1.23 % | $ 8.42 B | ||
|
Guardant Health
GH
|
-437 M | $ 88.91 | 1.18 % | $ 11.1 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | ||
|
Interpace Biosciences
IDXG
|
4.08 M | $ 1.98 | -2.37 % | $ 8.76 M | ||
|
Illumina
ILMN
|
-833 M | $ 127.88 | 1.95 % | $ 20.3 B | ||
|
National Research Corporation
NRC
|
22.6 M | $ 17.23 | -0.12 % | $ 386 M | ||
|
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.47 | -0.58 % | $ 20 B | ||
|
Personalis
PSNL
|
-68.3 M | $ 6.1 | 3.39 % | $ 361 M | ||
|
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
-5.14 M | $ 2.14 | -0.47 % | $ 4.92 M | ||
|
ICON Public Limited Company
ICLR
|
1.1 B | $ 102.17 | -3.92 % | $ 8.43 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 263.8 | -0.43 % | $ 21.9 B | ||
|
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | ||
|
Celcuity
CELC
|
-172 M | $ 121.03 | 6.58 % | $ 5.66 B | ||
|
Thermo Fisher Scientific
TMO
|
7.75 B | $ 469.71 | 0.64 % | $ 177 B | ||
|
NeoGenomics
NEO
|
-116 M | $ 8.29 | 4.8 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
-1.06 B | $ 9.54 | 2.03 % | $ 2.07 B | ||
|
Twist Bioscience Corporation
TWST
|
-136 M | $ 60.94 | 3.55 % | $ 3.64 B | ||
|
Myriad Genetics
MYGN
|
-387 M | $ 4.78 | -0.21 % | $ 443 M | ||
|
Natera
NTRA
|
-541 M | $ 203.75 | 1.3 % | $ 20.1 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 196.27 | -1.66 % | $ 21.8 B | ||
|
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
-12.6 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | ||
|
Waters Corporation
WAT
|
271 M | $ 309.87 | -0.43 % | $ 18.5 B |